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Summary
Background The emergence of programmatically incurable tuberculosis threatens to destabilise control efforts. 
The aim of this study was to collect prospective patient-level data to inform treatment and containment strategies.
Methods In a prospective cohort study, 273 South African patients with extensively drug-resistant tuberculosis, or 
resistance beyond extensively drug-resistant tuberculosis, were followed up over a period of 6 years. Transmission 
dynamics, infectiousness, and drug susceptibility were analysed in a subset of patients from the Western Cape using 
whole-genome sequencing (WGS; n=149), a cough aerosol sampling system (CASS; n=26), and phenotypic testing for 
18 drugs (n=179).
Findings Between Oct 1, 2008, and Oct 31, 2012, we enrolled and followed up 273 patients for a median of 20·3 months 
(IQR 9·6–27·8). 203 (74%) had programmatically incurable tuberculosis and unfavourable outcomes (treatment 
failure, relapse, default, or death despite treatment with a regimen based on capreomycin, aminosalicylic acid, or 
both). 172 (63%) patients were discharged home, of whom 104 (60%) had an unfavourable outcome. 54 (31%) home-
discharged patients had failed treatment, with a median time to death after discharge of 9·9 months (IQR 4·2–17·4). 
35 (20%) home-discharged cases were smear-positive at discharge. Using CASS, six (23%) of 26 home-discharged 
cases with data available expectorated infectious culture-positive cough aerosols in the respirable range (<5 μm), and 
most reported inter-person contact with suboptimal protective mask usage. WGS identified 17 (19%) of the 90 patients 
(with available sequence data) that were discharged home before the diagnosis of 20 downstream cases of extensively 
drug-resistant tuberculosis with almost identical sequencing profiles suggestive of community-based transmission 
(five or fewer single nucleotide polymorphisms different and with identical resistance-encoding mutations for 
14 drugs). 11 (55%) of these downstream cases had HIV co-infection and ten (50%) had died by the end of the study. 
22 (56%) of 39 isolates in patients discharged home after treatment failure were resistant to eight or more drugs. 
However, five (16%) of 31 isolates were susceptible to rifabutin and more than 90% were likely to be sensitive to 
linezolid, bedaquiline, and delamanid.
Interpretation More than half of the patients with programmatically incurable tuberculosis were discharged into the 
community where they remained for an average of 16 months, were at risk of expectorating infectious cough aerosols, 
and posed a threat of transmission of extensively drug-resistant tuberculosis. Urgent action, including appropriate 
containment strategies, is needed to address this situation. Access to delamanid, bedaquiline, linezolid, and rifabutin, 
when appropriate, must be accelerated along with comprehensive drug susceptibility testing.
Funding UK Medical Research Council, South African Medical Research Council, South African National Research 
Foundation, European & Developing Countries Clinical Trials Partnership, Oppenheimer Foundation, Newton Fund, 
Biotechnology and Biological Sciences Research Council, King Abdullah University of Science & Technology.
Introduction
Resistance to antituberculosis drugs has emerged as a 
serious and pressing global health concern.1 During the 
past decade, widespread resistance to rifampicin and 
isoniazid (multidrug resistance) has been supplanted by 
additional resistance to fluoroquinolones and the second-
line injectable drugs amikacin, kanamycin, and capreo-
mycin (extensive drug resistance),2,3 and now resistance 
beyond extensive drug resistance (known as totally 
drug-resistant tuberculosis, a non-standardised definition) 
has emerged.4 Multidrug-resistant and extensively drug-
resistant tuberculosis drive roughly a quarter of global 
tuberculosis mortality,1 are unsustainably costly to treat,5–8 
and pose a major threat to health-care workers.9
In 2014 there were almost 500 000 cases of multidrug-
resistant tuberculosis globally, and 18 734 reported cases of 
rifampicin-resistant or multidrug-resistant tuberculosis in 
South Africa (of which roughly 8% were thought to be 
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extensively or totally drug resistant).10,11 Further resistance 
to the drugs used to treat extensively drug-resistant disease 
has resulted in patients for whom a treatment regimen 
cannot be constructed with the drugs available in the 
national programme and who thus have programmatically 
untreatable tuberculosis.4,10,12,13 Estimates from Africa, 
Russia, India, and China suggest that treatment fails to 
cure 30–75% of patients with extensively or totally drug-
resistant tuberculosis.14–18 New drugs such as bedaquiline,19,20 
and repurposed ones such as linezolid,21–23 have become 
available in some settings. However, in many countries 
access is severely limited and the inability to construct an 
effective regimen using at least four effective drugs 
(despite the availability of newer agents) has rendered 
many patients impossible to treat effectively. Patients in 
whom treatment has failed are often discharged to home 
care in the community.4 The epidemiology and long-term 
outcomes beyond 2 years for these patients have not been 
comprehensively and prospectively studied, and potentially 
effective drug combinations for such cases of treatment 
failure remains unclear. Furthermore, the capacity of these 
patients to transmit disease is not known, and although 
Research in context
Evidence before this study
Reports of programmatically incurable tuberculosis (cases of 
treatment failure in extensively drug-resistant tuberculosis) 
have come from countries with a high tuberculosis burden, 
including China, India, and South Africa. The poor cure rates, 
high economic cost, and drain on scarce resources of treatment 
for drug-resistant tuberculosis threatens to destabilise 
tuberculosis control efforts in affected countries. We searched 
PubMed for articles published in all languages up to Aug 1, 2016, 
with the terms “XDR-TB” or “XDR-TB” and “treatment failure” 
and “outcome”. Of 44 articles identified, ten described 
treatment failure in extensively drug-resistant tuberculosis, 
two of which concerned the same cohort. Only one study 
followed up cases of treatment failure to document duration to 
hospital discharge and post-discharge outcomes including 
survival. This South African study described a short prospective 
follow-up of a retrospectively selected cohort and 
post-discharge outcomes in only 19 cases of treatment failure in 
extensively drug-resistant tuberculosis. Median survival of 
patients who had failed treatment from time of discharge was 
19·84 months (IQR 4·16–26·04). Infectiousness and 
transmission dynamics to elicit the magnitude of 
community-based transmission was not undertaken. No further 
articles reporting follow-up of treatment failure in extensively 
drug-resistant tuberculosis were identified. Similarly, a search of 
PubMed using the terms “XDR” or “MDR” and “TB” and 
“infectiousness” revealed no studies assessing the infectiousness 
of individual patients with drug-resistant tuberculosis.
Added value of this study
We describe a large prospective study of clinical outcomes and 
longevity in home-discharged patients with tuberculosis 
resistant to first-line and second-line drugs and for whom a 
curative treatment regimen was not available. More 
importantly, to our knowledge, our data about respirable 
aerosols infected with Mycobacterium tuberculosis expelled 
during coughing in this study are the first to describe the 
infectiousness of individual patients with programmatically 
incurable tuberculosis. The accompanying whole-genome 
sequencing data from M tuberculosis isolates provides evidence 
of transmission and post-discharge generation of secondary 
cases in the community with high mortality. Previous study 
findings have suggested nosocomial transmission of 
extensively drug-resistant tuberculosis, but here we provide 
evidence that highly drug-resistant strains are spreading in the 
community from home-discharged patients and generating 
secondary cases with poor outcomes. These data challenge 
previously held assumptions that highly drug-resistant 
mycobacteria have reduced fitness and diminished capacity to 
infect new patients. Our findings also show that, although 
survival is poor, patients can reside in the community for 
months or years after discharge home and before death. 
Evidence presented for regimens likely to be effective include 
the description of rifabutin-sensitive cases despite resistance to 
rifampicin.
Implications of all the available evidence
Evidence from this large, prospective study shows that 
home-discharged patients with infectious, highly 
drug-resistant tuberculosis survive for considerable periods of 
time and, more importantly, are a source of transmission, 
which has serious implications for public health. Previous 
evidence of nosocomial transmission of extensively 
drug-resistant tuberculosis, such as the outbreak associated 
with an HIV clinic in Tugela Ferry, demonstrate the crucial 
importance of infection control. Our findings highlight an 
urgent need to interrupt transmission in communities. The 
increasing incidence of extensively drug-resistant tuberculosis 
reported by WHO and reports of programmatically incurable 
tuberculosis from countries such as China and India indicate 
that such patients are not unique to South Africa. Investment 
is urgently needed to halt the rise of programmatically 
incurable tuberculosis that risks taking us back to the 
pre-antibiotic era. Cure rates are enhanced by use of the new 
and repurposed drugs (bedaquiline, delamanid, and linezolid) 
but are hampered by their lack of availability in many 
countries. Poor access to drug susceptibility tests and empirical  
treatment of drug-resistant disease risks amplification of 
resistance when a curative regimen might no longer be 
possible. Thus, the available evidence indicates an urgent need 
to rollout new drugs and drug resistance testing, reduce 
opportunities for transmission, and facilitate care for 
individuals with highly resistant and incurable tuberculosis 
when discharged from hospital.
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the transmission of drug-resistant bacteria is thought to be 
attenuated compared with susceptible bacteria,24 the 
detection of drug-resistant tuberculosis has increased in 
several high-burden countries, and serious epidemics are 
unfolding in others including South Africa, India, Russia, 
and several countries in eastern Europe and central Asia.25
To interrogate these questions, we did a long-term 
prospective study in patients with extensively drug-
resistant tuberculosis who received treatment regimens 
based on aminosalicylic acid, capreomycin, or both 
according to prevailing national guidelines at the time. 
We postulated that a substantial proportion of home-
discharged patients with extensively drug-resistant 
tuberculosis that had not responded to treatment would 
remain infectious and generate secondary cases of 
extensively drug-resistant tuberculosis in the community. 
We thus undertook whole-genome sequencing of 
baseline Mycobacterium tuberculosis culture isolates and 
did cough aerosol sampling to quantify the infectiousness 
of individual patients.
Methods
Study design and participants
Between Oct 1, 2008, and Oct 31, 2012, we recruited all 
adult patients with microbiologically confirmed, extensively 
drug-resistant tuberculosis (defined as resistance to at least 
rifampicin, isoniazid, a fluoroquinolone, and a second-line 
injectable) who were admitted to two South African 
treatment facilities (Brooklyn Chest Hospital, Western 
Cape, and Harry Surtie [previously Gordonia] Hospital, 
Northern Cape; figure 1A). Both hospitals are designated 
specialist referral centres for the treatment of all patients 
diagnosed with extensively drug-resistant tuberculosis 
within their province. All patients with extensively 
drug-resistant tuberculosis who initiated treatment were 
admitted to the designated hospitals during the study 
period and received a treatment regimen based on 
aminosalicylic acid, capreomycin, or both according to 
prevailing national guidelines at the time (linezolid and 
bedaquiline were not available within the tuberculosis 
programme). Patients were followed up until Oct 31, 2014 
(the study censor date), or death. Patients were reviewed in 
hospital and data was captured on a quarterly basis by a 
trained researcher using a standardised case record form. 
Discharged patients were contacted by telephone and 
visited at their homes, and treatment in the continuation 
phase was directly observed. Sputum samples were 
collected monthly for smear microscopy and culture. 
Further laboratory and clinical investigations were done 
only on patients or samples from Brooklyn Chest Hospital 
in the Western Cape (n=204) and were dependent on the 
availability of samples. This included extended drug 
susceptibility testing to 18 drugs (rifampicin, isoniazid, 
amikacin, kanamycin, streptomycin, cycloserine, 
ethionomide, ethambutol, moxifloxacin, ofloxacin and 
aminosalicylic acid, capreomycin, dapsone, clarithromycin, 
clofazimine, linezolid, pyrazinamide, and rifabutin; n=179), 
next-generation whole-genome sequencing (n=153), and 
cough aerosol sampling (n=26; figure 1B). Thus, further 
investigations were not undertaken on patients or samples 
from the Harry Surtie Hospital in the Northern Cape.
Ethical approval was obtained from the University of 
Cape Town Human Research Ethics Committee and 
participants provided informed written consent.
Procedures
A 5-year study period, including recruitment and 
follow-up, was selected to enable the recruitment of a 
sizable cohort and to allow for the assignment of 
programmatic treatment outcomes. Treatment duration 
for extensively drug-resistant tuberculosis is 24 months, 
and therefore at least 2 years of follow-up are required. 
We routinely recorded death during follow-up (table, 
figure 2). We additionally recorded programmatic 
treatment outcomes at 24 months and 60 months, 
including death, as outlined in the WHO definitions 
and reporting framework (adapted when appropriate; 
appendix p 10).26 We also assessed the proportion of 
patients who were cured, completed treatment, had 
treatment failure, died while on treatment, relapsed, 
defaulted, and had ongoing treatment. In patients who 
were discharged home, we defined death while on 
treatment as deaths in patients who were receiving 
futile treatment (token oral treatment with one or two 
oral agents [eg, pyrazinamide and ethambutol] was 
often given for perceived humanitarian reasons by the 
clinician in charge). Clinical primary disease was 
defined as any patient with at least one of the following: 
no previous tuberculosis episode, drug-susceptible 
tuberculosis cured more than 12 months before the 
current diagnosis, first empirical treatment for drug-
susceptible tuberculosis 9 months or less before the 
current diagnosis, or pre-extensively drug-resistant 
tuberculosis (resistance to rifampicin, isoniazid, and 
either a fluoroquinolone or an aminoglycoside) 
6 months or less before the current diagnosis (full 
definitions are given in the appendix, p 11). Capreomycin 
was prescribed according to the national guidelines 
because linezolid and bedaquiline were not available 
within the national tuberculosis programme at the 
time. Capreomycin was used even when isolates were 
phenotypically resistant, due to the paucity of other 
therapeutic options and the drug’s high serum to 
minimum inhibitory concentration ratio (thus possibly 
still providing therapeutic benefit). Further details of 
methodology are presented in the appendix (p 6).
Drug susceptibility testing
Phenotypic drug susceptibility testing was done by the 
National Health Laboratory Service in accordance with the 
national tuberculosis programme guidelines; included 
second-line drugs were ofloxacin, amikacin, ethionamide, 
and (in a subset of patients, at the request of the attending 
clinician) capreomycin. Additional testing was done on 
See Online for appendix
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186 available isolates from Brooklyn Chest Hospital using 
Sensititre MYCOTB MIC plates (Trek Diagnostic Systems, 
Cleveland, OH, USA) to establish minimum inhibitory 
concentrations for rifampicin, isoniazid, amikacin, 
kanamycin, streptomycin, cycloserine, ethionomide, 
ethambutol, moxifloxacin, ofloxacin, and aminosalicylic 
acid. Resistance to capreomycin, dapsone, clarithromycin, 
clofazimine, linezolid, pyrazinamide, and rifabutin was 
determined using the BD BACTEC mycobacterial growth 
indicator tube (MGIT; Becton Dickinson Diagnostic 
Systems, Sparks, MD, USA; further details are provided 
in the appendix, p 6). Sensititre or MGIT results were 
used in analyses if discrepancies were observed compared 
with programmatic drug susceptibility testing. We did a 
secondary analysis excluding discrepant patients to rule 
out possible bias from misclassified samples.
Further investigations were not undertaken in patients 
from the Northern Cape province because of logistical 
(inability and lack of approval to transport highly 
infectious material) and regulatory (provincial and ethical 
approvals could not be obtained) reasons.
Genome analysis
We used IS6110 restriction fragment length polymorphism 
(RFLP) fingerprinting to assess available M tuberculosis 
MGIT cultures from the sputum of patients from 
Brooklyn Chest Hospital (n=165).27 We did whole-genome 
sequencing on extracted DNA (n=153; more details are 
provided in the appendix, p 7) using Illumina HiSeq2000 
technology (available at European Nucleotide Archive with 
accession PRJEB14199).28 The data processing pipeline 
that we used has been described previously.29 We mapped 
Figure 1: Study design
(A) Patient outcomes, assessed in whole cohort. (B) Further investigations, assessed in patients from Brooklyn Chest Hospital only. XDR-TB treatment regimens were 
based on aminosalicylic acid or capreomycin. XDR-TB=extensively drug-resistant tuberculosis. DST=drug susceptibility testing. RFLP=restriction fragment length 
polymorphism. SNP=single nucleotide polymorphism. *Four samples failed quality control for genotypic drug resistance analysis; of the remaining 149 readouts, 
141 passed quality control for SNP analysis. Of these, 90 were from isolates belonging to home-discharged cases; thus, there were 90 home-discharged cases that had 
isolates with valid whole-genome sequences. †Cough aerosol sampling was done after diagnosis of extensively drug-resistant tuberculosis, but not necessarily exactly 
6 months after diagnosis. Phenotypic drug susceptibility testing was done at the time of cough aerosol sampling in 20 patients. Contact reporting was assessed in 
13 patients who underwent cough aerosol sampling.
A
69 Harry Sutrie Hospital 
Northern Cape province
At censor date Oct 31, 2014:
43 cured or completed treatment
203 unfavourable outcomes
67 treatment failed
46 defaulted or relapsed
90 died while on treatment
24 transferred out or lost to follow-up
3 treatment ongoing
172 discharged home before censor date
42 cured or completed treatment
104 unfavourable outcomes
54 treatment failed
56 defaulted or relapsed
14 died while on treatment
24 transferred out or lost to follow-up
2 treatment ongoing
204 Brooklyn Chest Hospital 
Western Cape province
40 excluded from study
20 XDR-TB treatment not initiated
8 died
9 no consent
3 insufficient data
313 patients laboratory confirmed XDR-TB and admitted to
hospital in the Northern Cape or Western Cape province
273 XDR-TB treatment regimen initiated
B
204 underwent microbiological and genotypic investigation at
 XDR-TB diagnosis
179 extended DST for 18 drugs
19 no isolate available
6 reculture unsuccessful
165 IS6110-RFLP genotyping
19 no isolate available
20 reculture or DNA extraction unsuccessful
153 whole-genome sequencing*
19 no isolate available
21 reculture or DNA extraction unsuccessful
11 whole-genome sequencing technically unsuccessful
Microbiological, genotypic, and infectiousness-related 
investigation at least 6 months after initial XDR-TB diagnosis
14 extended DST for 18 drugs
139 culture negative or patient deceased
24 reculture unsuccessful
26 whole-genome sequencing
139 culture negative or patient deceased
24 reculture unsuccessful
15 DNA extraction whole-genome sequencing
unsuccessful or no diagnostic isolate available
26 cough aerosol sampling†
178 patient deceased or system not yet validated and
operational
69 in Harry Sutrie hospital did not receive
further investigation
273 received XDR-TB treament regimen
204 in Brooklyn Chest Hospital had further investigation
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raw sequence data uniquely to the corrected H37Rv 
reference genome (Genbank accession AL123456.3) using 
bwa-mem (v0.7) software. We used SAMtools (v1.2) and 
GATK (v3.3-0) to call single nucleotide polymorphisms 
(SNPs) and indels. Variants with quality scores of Q30 or 
higher, equating to one error per 1000 base positions, were 
selected for further analysis. Genotypes were called in 
positions of ten-fold coverage; otherwise positions were 
classified as missing. Highly repetitive and variable 
regions were removed by calculating mappability values 
along the reference genome using a k-mer length of 
50 base pairs and 0·04% of allowed substitutions while 
mapping. Isolates with a high proportion of missing 
SNP positions (>10%) were excluded. Large indels and 
structural variants were identified with Pindel (version 
0.2.4w) and Delly2 (version 0.7.3). Phylogenetic analysis 
was performed with RAxML tree software (v8) with a 
general time-reversible model and gamma correction for 
among-site rate variation using 1000 random bootstrap 
replicates.
To calculate the number of SNPs differing between 
isolates, we first removed all mutations associated with 
drug resistance, then clustered isolates by lineage, and 
filtered out isolates with a proportion of missing calls 
greater than 10%. Positions where any isolate in a cluster 
had a missing call were removed and the number of SNPs 
differing between two isolates were calculated. Finally, we 
compared mutations associated with drug resistance 
between isolates. This process was repeated within each 
cluster until no further separation was observed. We used 
a threshold of five or fewer SNP differences and identical 
markers of drug resistance in genes encoding for 14 drugs 
(amikacin, capreomycin, ethambutol, ethionamide, 
fluoroquinolones, isoniazid, kanamycin, aminosalicylic 
acid, pyrazinamide, rifampicin, streptomycin, linezolid, 
bedaquiline, clofazimine) when assigning transmission 
events.30,31 Phylogenetic trees and interaction networks 
were created using the R packages ape (v 3.3) and qgraph 
(v1.3.1), respectively.
Genotypic drug resistance
Samples with inadequate sequence coverage of the genes 
responsible for resistance to rifampicin and isoniazid 
were removed from the analysis. Variants were analysed 
against known resistance markers and resistance-
conferring genes for each of the major antituberculosis 
drugs32 and the newer and repurposed drugs (bedaquiline, 
clarithromycin, delamanid, linezolid, pretomanid [PA-
824; Global Alliance for TB Drug Development, New 
York, NY, USA], rifabutin, SQ109 [Sequella, Rockville, 
MD, USA], sutezolid [PNU-100480; Sequella], and 
TBA-354 [Global Alliance for TB Drug Development]; 
appendix p 7). Pyrazinamide resistance included all 
variants in pncA except those reported not to cause 
resistance.33 Isolates with less than ten-depth coverage or 
a low confidence structural variant at a resistant marker 
and no positive resistant marker for the drug under 
investigation were excluded. For rifabutin, mutations at 
codon 516* (Asp526Thr/Ser/Val) in rpoB (Rv0667) were 
removed because they do not increase the minimum 
inhibitory concentration of rifabutin to above the critical 
threshold of 0·5 μg/mL.34 Similarly, the naturally 
occurring variant Arg409Gln in Rv1979c (clofazimine 
resistance gene) was excluded.
Cough aerosol sampling
The cough aerosol sampling system is a newly validated 
technology; its readings positively correlate with tuberculin 
Alive Deceased Total p value for 
mortality*
All patients with extensively drug-resistant tuberculosis
Number of patients 87 (32%) 186 (68%) 273 ··
Sex 0·90
Men 50 (57%) 104 (56%) 154 (56%) ··
Women 37 (43%) 82 (44%) 119 (44%) ··
Race 0·19
Mixed ancestry 44 (51%) 109 (59%) 153 (56%) ··
Black 43 (49%) 77 (41%) 120 (44%) ··
Age at diagnosis, years 32·62 
(26·51–38·29)
35·39 
(26·83–44·19)
34·27 
(26·52–42·88)
0·10
HIV infected 37 (43%) 82/185 (44%) 119/272 (44%) 0·93
CD4 count, cells per μL 207·5 (70–342·3) 199·5 (89–315) 199·5 (85·8–323) 0·68
Patients with HIV receiving 
antiretroviral therapy
34 (39%) 74 (40%) 108 (40%) 1·00
Weight at XDR-TB diagnosis 
≤50 kg
29/85 (34%) 103/185 (56%) 132/270 (49%) <0·0001
Number of drugs in XDR-TB 
tuberculosis regimen
9 (8–10) 9 (8–10) 9 (8–10) 0·11
Follow-up since XDR-TB 
diagnosis, months
25·5 (18·9–29·4) 15·3 (7·3–26·4) 20·3 (9·6–27·8) <0·0001
Primary XDR-TB† 32 (37) 59 (32) 91 (33) 0·41
Patients discharged home
Total 83 (48%) 89 (52%) 172 ··
Sex 0·60
Men 48 (58%) 56 (63%) 104 (60%) ··
Women 35 (42%) 33 (37%) 68 (40%) ··
Race 0·10
Mixed ancestry 41 (49%) 56 (63%) 97 (56%) ··
Black 42 (51%) 33 (37%) 75 (44%) ··
HIV-infected 35 (41%) 35 (39%) 70 (41%) 0·82
CD4 count, cells per μL 243 (104·0–330·5) 184 (68·0–326·2) 217 (85·0–335·0) 0·55
Positive smear status at 
XDR-TB diagnosis
25/69 (36%) 30/81 (37%) 55/150 (37%) 1·00
Weight at XDR-TB diagnosis 
≤50 kg
27/81 (34%) 43/89 (48%) 70/170 (41%) 0·068
Number of drugs in XDR-TB 
regimen
9 (8, 10) 9 (8, 10) 9 (8, 10) 0·89
Table shows data for patients with XDR-TB diagnosed between Oct 1, 2008, and Oct 31, 2012, stratified by mortality 
status by the end of the study. Data are n (%) or median (IQR). Denominators are given when they do not match the 
total sample size (as a result of missing data). XDR-TB=extensively drug-resistant tuberculosis. *Difference between 
alive and deceased groups. †For definition refer to appendix.
Table: Demographic characteristics
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skin test conversion and incident tuberculosis in 
household contacts of index patients with active 
tuberculosis.35 A cough aerosol sampling system was 
installed at Brooklyn Chest Hospital towards the end of the 
study (February, 2013), and was thus only done on a subset 
of 26 patients admitted to Brooklyn Chest Hospital. The 
system enumerates culturable, respirable cough aerosol 
particles (<5 µm; able to reach the alveolar compartment) 
to assess the infectiousness of individual patients.36–38 
Briefly, patients were asked to cough into a sterile chamber 
containing a six-stage Andersen cascade impactor (Thermo 
Scientific, Rockford, IL, USA) that collects airborne 
particles of known size distribution (appendix p 8). Patients 
coughed as frequently as was comfortable for two 5 min 
sessions, separated by a rest of approximately 5 min. 
Cough aerosol particles were deposited on 7H11 media 
(BD Biosciences, San Jose, CA, USA), supplemented with 
Mycobacteria Selectatab (Kirchner Mast Group, 
Merseyside, UK). Colony-forming units of M tuberculosis 
from droplets in the respirable range were recorded after 
incubation at 37°C. Sputum specimens collected during 
the cough aerosol sampling system visit were processed 
for smear microscopy, culture, and phenotypic drug 
susceptibility testing. After sampling, patients were 
provided with surgical facemasks and requested to report 
mask usage and contact with other individuals.
Figure 2: Kaplan-Meier survival estimates for probability of survival
(A) Survival since diagnosis in all patients with extensively drug-resistant tuberculosis, stratified by HIV status (n=272; one patient refused testing and was not included in this analysis). (B) Survival since 
discharge from hospital for home-discharged patients stratified by favourable vs unfavourable outcomes (n=148; 172 patients were discharged home but patients who were lost to follow-up and 
transferred out were not included in this analysis). Unfavourable outcomes are divided into treatment default, treatment failure with no further therapy (death while on no treatment), and treatment 
failure with death while receiving ineffective treatment after discharge. (C) Survival since discharge from hospital for home-discharged patients by type of unfavourable outcome (treatment failed and not 
on therapy, defaulted and not on therapy, or death while on treatment; n=144 [two patients relapsed and two patients had ongoing treatment, so were not included in this analysis]). HRs were calculated 
vs a favourable outcome (ie, cure or treatment completion; n=42). (D) Survival since discharge from hospital in home-discharged patients with unfavourable outcomes stratified by smear status at 
discharge (n=104). HR=hazard ratio. XDR-TB=extensively drug-resistant tuberculosis. *HR 6·82 (95% CI 2·29–20·31); p=0·00056. †HR 18·59 (95% CI 6·61–52·33); p<0·0001. ‡HR 52·54 
(95% CI 16·75–164·982); p<0·0001.
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Statistical analysis
We calculated medians and IQRs for continuous variables 
and frequency (percent) for categorical variables. We 
compared continuous variables with Wilcoxon rank sum 
tests and categorical variables with χ² tests. Kaplan-Meier 
curves were estimated for the probability of survival 
either from date of diagnosis or date of discharge. End of 
follow-up was date of death, date of loss to follow-up, or 
censor date. Comparisons between strata (eg, HIV-
infected vs HIV-uninfected individuals) were made by the 
log-rank test. Univariate Cox proportional hazards models 
were used to estimate the relation between explanatory 
variables and time-to-event outcomes. We included the 
variables of HIV status, antiretroviral therapy status, sex, 
race, treatment outcome (favourable or unfavourable), 
M tuberculosis lineage, smoking, education, weight at 
diagnosis, age at diagnosis, number of drugs prescribed, 
history of tuberculosis, and history of multidrug-resistant 
tubercu losis, and a binary variable for each of the drugs 
prescribed. Multivariate Cox proportional hazards models 
for mortality included variables that were significantly 
associated with outcome (p<0·1) and the prespecified 
variables (sex, race, education, HIV status). We used a 
90% threshold so that we would not exclude variables 
that, although not significant at an alpha of 0·05 in 
univariate analysis, might be significant in a multivariate 
analysis. The underlying proportional hazards 
assumption was assessed using the (weighted) scaled 
Schoenfeld residuals test. We regarded p values as 
statistically significant at a nominal value of p<0·05, but 
in view of the large number of exploratory outcomes 
significance should not be taken as confirmatory. Thus, 
patients were included in the analysis that were still in the 
study at the time the measurement under investigation 
was taken, and for whom a result was available, even if 
they were later lost to follow-up. Statistical analysis was 
done in in R (version 3·0) and graphics generated with 
the package ggplot2.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. KD, JDL, EP, and RM had full 
access to the raw data. The corresponding author had full 
access to all of the data and the final responsibility to 
submit for publication.
Results
273 patients, 204 (75%) from Brooklyn Chest Hospital 
and 69 (25%) from Harry Surtie Hospital, were recruited 
into the study. Patient demographics are summarised in 
the table and the appendix (p 15). 119 (44%) patients had 
HIV, with a median CD4 cell count of 199·5 cells per μL 
(IQR 85·8–323·0). All but five patients with HIV were on 
antiretroviral therapy. We noted clinically defined, 
primary tuberculosis with extensive drug-resistance in 
91 (33%) patients.
The median duration of follow-up was 20·3 months 
(IQR 9·6–27·8). At censor date, 186 (68%) patients had 
died (table). 203 (74%) patients had unfavourable treatment 
outcomes (treatment failure, treatment default, relapse, or 
death while on treatment; appendix p 16), and thus 
programmatically incurable tuberculosis. Multivariate 
analysis showed that bodyweight of 50 kg or more 
(p<0·0001), increased time to culture positivity (p<0·0001), 
increased age at diagnosis (p=0·004), and treatment with 
aminosalicylic acid (p=0·001) were associated with survival 
(appendix p 19).
172 (63%) patients were home discharged from hospital 
into the community; patient outcomes are summarised in 
the appendix (p 25). 53 (31%) of these patients had died in 
the first 12 months after discharge and 89 (52%) had died 
by the end of study. Unfavourable outcomes occurred in 
104 (60%) of home-discharged patients (appendix p 25) 
with treatment failing in 54 (31%); 43 (80%) of these 
patients later died. Their median time to death after home-
discharge was 9·9 months (IQR 4·2–17·4). Positive 
sputum smear results were recorded for 35 (20%) of home-
discharged patients a median of 21·0 days (IQR 10·5–36·0) 
from discharge, and were associated with reduced 
longevity (figure 2). 
We noted high levels of drug resistance for first-line 
and second-line drugs (figure 3, appendix p 13). For 
logistical and regulatory reasons, phenotypic drug 
susceptibility testing to 18 antitubercu losis drugs was 
done only on patient isolates from Brooklyn Chest 
Hospital, accounting for 179 (66%) of the total cohort 
(figure 1B). 135 (75%) patients were resistant to eight or 
more drugs, 77 (43%) were resistant to ten or more drugs, 
and four (2%) were resistant to a maximum of 13 drugs.
Whole-genome sequencing of the 149 isolates that 
passed quality control for genotypic drug resistance 
analysis showed few mutations associated with resistance 
to new, novel, and repurposed drugs (figure 3, appendix 
p 20). One isolate had an Ser68Asn mutation in the 
Rv0678 gene, thought to be likely predictive of 
bedaquiline resistance.39
SNP analysis suggested susceptibility to rifabutin in 
34 (23%) of the 149 extensively drug-resistant tuberculosis 
isolates sequenced; confirmatory phenotypic drug 
susceptibility testing was done with the MGIT 960 system 
and 32 (97%) of 34 isolates were rifabutin sensitive at a 
critical concentration of 0·5 μg/ml. Of the 31 home-
discharge cases with whole-genome sequencing data, five 
(16%) were confirmed as rifabutin-sensitive. Importantly, 
19 of the confirmed rifabutin-sensitive cases were in 
patients with unfavourable treatment outcomes (11 were 
home discharged and living in the community for a mean 
of 21·0 months [SD 14·2]).
Phenotypic analysis of sequential isolates collected at 
least 6 months after the initial diagnostic isolate showed 
that one (3%) of 34 isolates gained resistance to 
clofazimine (the patient did not receive clofazimine), 
six (21%) of 29 isolates gained resistance to dapsone (two 
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of the six patients had received dapsone), and four (67%) 
of six isolates gained resistance to capreomycin (all 
four patients received capreomycin; appendix p 21). Of the 
26 sequential isolate pairs examined by whole-genome 
sequencing, three (50%) of six patients who received 
capreomycin gained drug-specific resistance mutations 
(appendix p 22).
Whole-genome sequencing was performed on 
153 diagnostic patient isolates from Brooklyn Chest 
Hospital in the Western Cape (figure 1). Genotyping these 
isolates revealed lineage 2 (Beijing) strains to be dominant 
(appendix p 23). Genome sequences from 141 isolates 
passed quality control measures for SNP analysis. 16 (11%) 
of these isolates had evidence suggestive of hetero-
resistance (both wildtype and drug-resistance-conferring 
mutations). 11 had evidence of mixed infection (ie, more 
than one strain of M tuberculosis), two of which had 
evidence of heteroresistance.
Using longitudinal samples from our cohort, we 
calculated the median number of SNPs accumulated per 
isolate genome per year as 0·99 (95% CI 0·79–1·67), 
which translates into a five-SNP change (using the lower 
confidence limit) occurring over 38 months, compared 
with a median diagnostic time difference between any 
two patients with extensively drug-resistant tuberculosis 
of 14·1 months (IQR 6·4–23·3).
Interpatient comparisons showed substantial similarity 
between isolates. The proportion of isolates differing by one 
or fewer, two or fewer, or five or fewer SNPs from at least 
one other patient isolate while having identical genotypic 
drug resistance profiles were 25 (18%) of 141, 41 (29%) of 
141, and 65 (46%) of 141, respectively (appendix p 24). 
46 (18%) of 273 patients self-reported exposure to 
tuberculosis before their diagnosis and 12 (4%) self-reported 
exposure to individuals with known extensively drug-
resistant tuberculosis. Whole-genome sequencing or 
IS6110-RFLP data were available for six patient–contact 
pairs (appendix p 25). Whole-genome sequencing and 
RFLP data suggested transmission (five or fewer SNPs 
different, identical IS6110-RFLP patterns) in four of 
five cases with data available; in one case for which whole-
genome sequencing data were unavailable, we noted 
identical IS6110-RFLP patterns (appendix p 25).
Isolates from 37 (41%) of the 90 home-discharged patients 
from Brooklyn Chest Hospital with whole-genome 
sequencing data available were highly similar and clustered 
(five or fewer SNPs different and with identical resistance-
encoding mutations for 14 drugs; figure 4). The median 
time spent by these patients in the community after 
Figure 3: Genome-based analysis of polymorphisms predictive of resistance to 
antituberculosis drugs
(A) Heat map depicting the genotypic resistance patterns of 
149 Mycobacterium tuberculosis isolates obtained at diagnosis of extensively 
drug-resistant tuberculosis. Each row represents a single patient. The isolates are 
stratified according to treatment outcome. Newer drugs were not used in the 
treatment of these patients. (B) Proportion of the 149 isolates with 
resistance-associated mutations for a specific newer or repurposed antituberculosis 
drug (at least one nsSNP or structural variant in any gene related to the mechanism 
of action of the drug). Genes analysed are listed in the appendix (p 12). 60 (58%) of 
104 isolates were from patients discharged home; of those, 3/60 (5%) were 
resistant to bedaquiline, 3/60 (5%) to delamanid, 7/60 (12%) to clofazimine, and 
47/60 (78%) to rifabutin. ns=non-synonymous. SNP=single nucleotide 
polymorphism. *Pre-extensively drug-resistant tuberculosis isolates from patient 
taken within 3 months of a subsequent extensively drug-resistant tuberculosis 
diagnosis.
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discharge was 15·2 months (IQR 8·7–33·3), and 
20 remained living in the community at the censor date. 
17 (19%) patients were discharged home and living in the 
community before the diagnosis of 20 patients with 
extensively drug-resistant tuberculosis and highly similar 
genomic sequences (ie, ≤5 SNPs  different, and identical 
resistance-encoding mutations for 14 drugs), suggesting 
community-based transmission. The median time between 
home discharge and diagnosis of a secondary case was 
9·2 months (IQR 5·4–9·7), and 11 (55%) of the 20 possible 
secondary cases were HIV-infected. 12 (60%) of these 
secondary cases had unfavourable outcomes and ten (50%) 
had died by the end of the study.
The cough aerosol sampling technology became 
available only towards the end of the study period. 
26 smear-positive individuals underwent cough aerosol 
sampling system to assess their degree of infectiousness. 
One (4%) patient of 26 was cured, with the remaining 
25 (96%) patients having unfavourable outcomes. 
22 (85%) patients were home discharged with 11 (42%) 
living in the community at the time of testing. Six (23%) 
had positive cough aerosol cultures in the less than 5 μm 
respirable range and thus were highly infectious (appendix 
p 27). All six had an unfavourable outcome (four with 
treatment failure) and five of these six (19%) were 
discharged home. One secondary case thought to have 
arisen from a home-discharged patient was cough aerosol 
sampling system-positive. Phenotypic drug susceptibility 
testing showed resistance to an average of six of 11 drugs 
in 20 (77%) sputum culture isolates acquired at the time of 
cough aerosol sampling system (six isolates were culture 
negative or contaminated). 13 patients who underwent 
cough aerosol sampling self-reported contact with other 
individuals, with a median of five contacts per day 
Figure 4: Molecular epidemiology and transmission dynamics of extensively drug-resistant tuberculosis
(A) An interaction network showing the linkage of isolates with two or fewer SNPs difference, and three to five SNPs difference, and matching drug resistance 
markers. Asterisks indicate patients who were discharged home into the community. Arrows originate on the patient with the earliest XDR-TB diagnosis date; 
geographical origin of the patient refers to the district of residence at the time of diagnosis. 65 (46%) of 141 isolates are represented in 18 clusters, suggestive of 
transmission. The thick lines represent a patient discharged home before the diagnosis of subsequent extensively drug-resistant tuberculosis case with an almost 
identical genetic profile (the head of the arrow identifies the downstream case). Thus, 17 (19%) of 90 home-discharged patients probably caused a secondary case of 
extensively drug-resistant tuberculosis. (B) Timelines for patients with clustered isolates of five or fewer SNPs difference and matching drug resistance markers. The 
median duration from diagnosis of extensively drug-resistant tuberculosis to end of follow-up was 20·3 months (IQR 9·6–27·8). The y-axis indicates clustered isolates 
with five or fewer SNP differences as in part (A). IS6110 restriction fragment length polymorphism patterns were within one band for all isolates in the respective 
clusters. 72% (47/65) of isolates remained when we assumed a closed network for interaction ≤5 and remove one isolate per node, indicating likely primary 
transmission in 33% (47/141) of patients. A map of districts is provided in the appendix (p 28). XDR-TB=extensively drug-resistant tuberculosis. SNP=single 
nucleotide polymorphism.
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(IQR 3·2–7·3) and a face mask not being worn for 458/610 
(75%) of these interactions (appendix p 27). RFLP data 
were available for three contact pairs (appendix p 27) and 
were suggestive of transmission in each case.
Discussion
To our knowledge, this study is the first prospective long-
term report on the outcomes and infectiousness of patients 
with extensively drug-resistant tuberculosis in whom 
treatment had failed, and hence in patients with 
programmatically incurable tuberculosis. Overall, un-
favourable outcomes occurred in 203 (74%) patients, with 
67 (33%) of these individuals having failed treatment. 
172 (63%) of all 273 patients in our study were discharged 
back into the community and 104 (60%) of these 
172 patients had an unfavourable outcome. Although such 
patients are perceived to be terminally ill, in reality the 
proportion of patients who had survived at 12 months after 
discharge was 21% (57 of 273). Continued treatment was a 
post-discharge predictor of mortality, although we believe 
this finding to be an analytical artifact due to selection bias 
(with those who were the sickest and with most extensive 
disease being more likely to receive treatment).
Our data demonstrate that uncured survivors with 
extensively drug-resistant tuberculosis have considerable 
longevity in the community, not dissimilar to the pre-
chemotherapeutic era when time to death occurred over 
years and roughly 20–30% of patients had chronic active 
disease.40 By contrast, we previously reported an overall 
survival rate of about 70% in home-discharged patients 
in whom treatment had failed in a retrospectively selected 
follow-up cohort, possibly reflecting selection and 
survival bias in that study.14 High rates of treatment 
failure in extensively drug-resistant tuberculosis have 
been described in several tuberculosis-endemic coun-
tries,14–16,18 and substantial patient longevity and trans-
mission from home-discharged patients within the 
community is likely to be occurring in such settings 
(although this has not yet been formally reported). In this 
study, both individuals with HIV infection and those 
without HIV infection were affected; multicentre studies 
are required to assess the global scale of this problem.
As demonstrated by cough aerosol sampling, six (23%) 
home-discharged patients assessed were highly infectious 
and a substantial proportion were smear positive. Culture-
positive cough aerosols in the respirable range are the 
best predictor of recent tuberculosis infection (tuberculin 
skin test conversion), and subsequent development of 
active tuberculosis in household contacts,35,37 although 
this method has limited scalability and potential as a 
public health intervention in view of its technical 
complexity, cost, time to result (6–8 weeks), and lack of 
portability (large, non-mobile equipment). We also noted 
high interperson contact scores and suboptimal mask 
usage among home-discharged patients.
We previously documented possible transmission from 
a single patient discharged home after treatment failure, 
causing a secondary case of extensively drug-resistant 
tuberculosis, in a retrospectively selected follow-up 
cohort.14 Here, we demonstrate that 17 (19%) home-
discharged patients with extensively drug-resistant 
tuberculosis might have caused a secondary case. One of 
the prerequisites for inferring such transmission was the 
absence of concurrent treatment at the same health-care 
facility (ie, the index cases of extensively drug-resistant 
tuberculosis were in the community before diagnosis of 
the secondary cases). This figure could be an under-
estimate, because it includes only secondary cases with 
development of active disease during the study period. 
Extended follow-up would be required to assess latently 
infected individuals who might progress to disease at a 
later date. Thus, transmission of extensively drug-
resistant tuberculosis from programmatically incurable 
patients discharged home is not uncommon. The 
mortality rate in secondary cases was substantial (50%), 
and we reiterate the urgent need to establish community-
based containment strategies. These strategies should 
include voluntary long-term community stay facilities 
and palliative care;41 few such amenities exist in 
tuberculosis-endemic settings.
We did whole-genome sequencing (using a threshold of 
five SNPs and matching drug-resistance markers) to 
study the molecular epidemiology of tuberculosis 
transmission. Although there are some drawbacks with 
the use of whole-genome sequencing to infer person-to-
person transmission, it is a well accepted approximation.30,31 
Investigators of previous studies have justified the use of 
a five-SNP threshold, showing its high predictive value to 
infer transmission.42,43 However, any threshold needs to 
be context-specific and related to mutation rate. Previously 
reported M tuberculosis mutation rates have varied 
between roughly 0·25 and 0·75 SNPs per genome per 
year in longitudinally sampled isolates from patients who 
were on antituberculosis treatment.30 The median 
number of SNPs accumulated per isolate genome per 
year, 0·99 (95 CI 0·79–1·67), translates into a five-SNP 
change (using the lower confidence limit) occurring over 
38 months; this figure is considerably more than the 
median duration of the diagnostic time difference 
between any two patients with extensively drug-resistant 
tuberculosis in our study of 14·1 months (IQR 6·4–23·3). 
Thus, although the use of SNP thresholds to infer 
resistance is contentious, we chose a conservative 
threshold of five SNPs, and additionally required that 
isolates had identical mutations in all resistance-encoding 
genes. When we omitted the requirement for identical 
resistance mutations, 100 (71%) of 141 isolates shared five 
or fewer SNP differences with at least one other isolate, 
compared with 65 (46%) of 141 isolates when this 
requirement was included in the analysis. Our estimates 
are therefore likely to be robust and have predictive value 
for inferring transmission.
We present evidence of transmission of extensively 
drug-resistant tuberculosis in that 65 (46%) isolates had 
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negligible genetic differences compared with at least one 
other patient isolate. This finding suggests that 
transmission is not uncommon in this setting. This 
situation is not unique to South Africa; reports from 
China suggest that almost half of extensively drug-
resistant tuberculosis is due to primary transmission.42 
Access to rapid molecular technologies, and newer and 
repurposed drugs such as bedaquiline, delamanid, and 
linezolid, are urgently needed in tuberculosis-endemic 
countries. South Africa has a programme that offers these 
drugs to a small number of patients, but they are not 
available to most patients in tuberculosis-endemic 
countries. Moreover, some individuals are denied access 
to these agents because of high-grade resistance that 
precludes the construction of an effective regimen. 
Although bedaquiline and linezolid are probably good 
choices to include in regimens against extensively drug-
resistant tuberculosis in this population, resistance to the 
nitroimidazoles is currently being reported, and treatment 
failures are already emerging. Findings from a 2016 
multicentre study of a bedaquiline-based regimen showed 
that 38% of patients with extensively drug-resistant 
tuberculosis had not culture converted by 30 months after 
treatment.44 Thus, there is and will continue to be a 
growing population of incurable tuberculosis cases in the 
community, underscoring the need for appropriate 
containment facilities to curtail transmission. Strategies 
to preserve new drugs should include prevention of 
pharmacokinetic mismatch and measures to ensure 
adherence.
In this context, a finding worthy of further investigation 
is the susceptibility to rifabutin of some rifampicin-
resistant strains. Although tentative, some data45 suggest 
that treatment of multidrug-resistant tuberculosis with 
rifabutin in appropriate patients improves outcomes 
compared with the use of conventional regimens. 
Additionally, more than 90% of isolates did not have 
mutations associated with resistance to linezolid, 
bedaquiline, or delamanid. A regimen with these agents 
could reduce mortality and infectiousness but, although 
approved for clinical use, these drugs are often inaccessible 
in tuberculosis-endemic countries; there is urgent need to 
accelerate rollout to where they are most needed.
There were several limitations to this study. We 
followed up outcomes in patients with extensively drug-
resistant tuberculosis who were admitted to hospital 
and receiving treatment, thus selection bias and 
survival bias might have affected the findings. However, 
during the period of this study local policy was to admit 
all patients diagnosed with extensively drug-resistant 
tuberculosis, which would have (if anything) under-
estimated poor outcomes because patients not 
diagnosed and thus not placed on treatment were not 
captured. However, these findings may be less 
generalisable to settings with low prevalence of HIV co-
infection. Indeed, we recruited all the patients in only 
two provinces of South Africa; in other provinces such 
as KwaZulu-Natal HIV co-infection rates are consider-
ably higher. Other limitations include missing data due 
to default and loss to follow-up, and the fact that cause 
of death was not ascertained. Few patient isolates 
underwent extended phenotypic drug susceptibility 
testing and whole-genome sequencing; however, these 
isolates were only accessible from the Western Cape 
province, where 91% (186/204) of isolates underwent 
extended drug susceptibility testing and 75% (153/204) 
underwent whole-genome sequencing. We were unable 
to present conclusive geospatial linkages between 
patients due to logistical constraints given the sheer 
burden of disease in this setting. Although we did 
identify clusters of active disease within friend and 
family groups, we did not comprehensively and actively 
screen all contacts for disease (which is currently not 
done within the national tuberculosis programme). 
However, in patients with demonstrated geospatial 
linkages, isolate genomes were very similar. Inadequate 
access to compounds for phenotypic drug susceptibility 
testing, lack of consensus about cutpoints, and 
incomplete knowledge of genotypic markers for 
resistance to the new and repurposed drugs precluded 
a full assessment of susceptibility to these drugs. 
Almost half of the patients tested with cough aerosol 
sampling who were discharged home after treatment 
failure were highly infectious.
In conclusion, treatment failure of extensively drug-
resistant tuberculosis, and hence programmatically 
incurable tuberculosis, is a nascent but growing 
phenomenon. Using innovative tools we have demon-
strated that substantial numbers of patients with highly 
drug-resistant and infectious tuberculosis are being 
discharged into the community after treatment failure 
and could be generating secondary cases of incurable 
tuberculosis. Data about these patients are vital to 
inform resource allocation and interventional strategies 
to contain this epidemic. Better approaches, including 
individualised treatment directed by whole-genome 
sequencing,46 use of effective regimens containing new 
and repurposed drugs, prevention of the amplification 
of resistance through optimal dosing and adherence 
promotion, and identification of the most infectious 
patients for transmission interruption strategies are 
urgently needed.
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